Refine
Year of publication
Institute
- Fachbereich Elektrotechnik und Informationstechnik (32)
- Fachbereich Medizintechnik und Technomathematik (5)
- Fachbereich Maschinenbau und Mechatronik (3)
- IfB - Institut für Bioengineering (3)
- Fachbereich Chemie und Biotechnologie (2)
- Fachbereich Luft- und Raumfahrttechnik (2)
- INB - Institut für Nano- und Biotechnologien (2)
- Fachbereich Energietechnik (1)
- Fachbereich Wirtschaftswissenschaften (1)
- Solar-Institut Jülich (1)
Has Fulltext
- no (45)
Document Type
- Article (19)
- Conference Proceeding (18)
- Part of a Book (7)
- Book (1)
Keywords
- MINLP (3)
- Engineering optimization (2)
- Experimental validation (2)
- Optimal Topology (2)
- Optimization (2)
- Powertrain (2)
- Process engineering (2)
- Pump System (2)
- Technical Operations Research (2)
- Water distribution system (2)
This chapter describes three general strategies to master uncertainty in technical systems: robustness, flexibility and resilience. It builds on the previous chapters about methods to analyse and identify uncertainty and may rely on the availability of technologies for particular systems, such as active components. Robustness aims for the design of technical systems that are insensitive to anticipated uncertainties. Flexibility increases the ability of a system to work under different situations. Resilience extends this characteristic by requiring a given minimal functional performance, even after disturbances or failure of system components, and it may incorporate recovery. The three strategies are described and discussed in turn. Moreover, they are demonstrated on specific technical systems.
LIGA-Technik zur Fertigung von Mikroaktoren. Ehrfeld. W.; Kämper, K.-P.; Lehr, H.; Michel, F.
(1993)
A technology reference study for a solar polar mission is presented. The study uses novel analytical methods to quantify the mission design space including the required sail performance to achieve a given solar polar observation angle within a given timeframe and thus to derive mass allocations for the remaining spacecraft sub-systems, that is excluding the solar sail sub-system. A parametric, bottom-up, system mass budget analysis is then used to establish the required sail technology to deliver a range of science payloads, and to establish where such payloads can be delivered to within a given timeframe. It is found that a solar polar mission requires a solar sail of side-length 100–125 m to deliver a ‘sufficient value’ minimum science payload, and that a 2.5 μm sail film substrate is typically required, however the design is much less sensitive to the boom specific mass.
Persistent infection with high-risk human papillomaviruses (hrHPV) can result in the formation of anogenital cancers. As hrHPV proteins E6 and E7 are required for cancer initiation and maintenance, they are ideal targets for immunotherapeutic interventions. Previously, we have described the development of DNA vaccines for the induction of HPV16 E6 and E7 specific T cell immunity. These vaccines consist of ‘gene-shuffled’ (SH) versions of HPV16 E6 and E7 that were fused to Tetanus Toxin Fragment C domain 1 (TTFC) and were named TTFC-E6SH and TTFC-E7SH. Gene-shuffling was performed to avoid the risk of inducing malignant transformation at the vaccination site. Here, we describe the preclinical safety evaluation of these candidate vaccines by analysis of their transforming capacity in vitro using established murine fibroblasts (NIH 3T3 cells) and primary human foreskin keratinocytes (HFKs). We demonstrate that neither ectopic expression of TTFC-E6SH and TTFC-E7SH alone or in combination enabled NIH 3T3 cells to form colonies in soft agar. In contrast, expression of HPV16 E6WT and E7WT alone or in combination resulted in effective transformation. Similarly, retroviral transduction of HFKs from three independent donors with both TTFC-E6SH and TTFC-E7SH alone or in combination did not show any signs of immortalization. In contrast, the combined expression of E6WT and E7WT induced immortalization in HFKs from all donors. Based on these results we consider it justified to proceed to clinical evaluation of DNA vaccines encoding TTFC-E6SH and TTFC-E7SH in patients with HPV16 associated (pre)malignancies.